secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2021-07-28T23:59:59+00:00
Accession:  0001564590-21-038623
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking reports Q2 net loss of $15.4M, cash $228.3M; VK2809 VOYAGE enrollment continues
--------------------------------------------------------------------------------

- Q2 net loss $15.4M ($0.20/sh) vs $9.6M ($0.13/sh) in Q2 2020; R&D expenses rose to $12.8M from $7.8M.
- Cash, equivalents and short-term investments $228.3M at June 30, down from $248.4M at Dec 31, 2020.
- Phase 2b VOYAGE study of VK2809 for NASH enrolling; top-line data expected in 2022.
- VK0214 Phase 1 met primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.
- Six-month net loss $29.4M ($0.38/sh) vs $19.3M ($0.27/sh) in H1 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/0001564590-21-038623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/vktx-8k_20210728.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-038623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer